Novo Nordisk A/S - share repurchase programme - July 20, 2026

Bagsværd, Denmark, 20 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027. Since the announcement 13 July 2026, the following transactions have been made: Number of B shares Average purchase price Transaction value, DKK Accumulated, last announcement 9,225,000 2,734,545,468 13 July 2026 195,000 322.69 62,923,858 14 July 2026 195,000 320.55 62,507,407 15 July 2026 195,000 323.83 63,147,108 16 July 2026 195,000 333.59 65,050,395 17 July 2026 195,000 333.35 65,003,163 Accumulated under the programme 10,200,000 3,053,177,399 The details for each transaction made under the share repurchase programme are published on novonordisk.com . With the transactions stated above, Novo Nordisk owns a total of 42,144,480 B shares of DKK 0.10 as treasury shares, corresponding to 0.9% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares. Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 17 July 2026, Novo Nordisk has since 4 February 2026 repurchased a total 24,959,179 B shares at an average share price of DKK 274.58 per B share equal to a transaction value of DKK 6,853,177,389. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. O ur purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes . We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information Media: Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com Investors: Michael Novod +45 3075 6050 nvno@novonordisk.com Sina Meyer +45 3079 6656 azey@novonordisk.com Max Ung +45 3077 6414 mxun@novonordisk.com Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com Alex Bruce +45 3444 2613 axeu@novonordisk.com Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com Company announcement No 43 / 2026 Attachments CA260720_Safe Harbour CA260720_safe harbour transaction details